Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 7/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | LSS | P48449 | 2/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.31 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
| ▸ | FEN1 | P39748 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21113917 | 0.90 | SCN9A (0.35) | SCN9ALSSSCN5AESR1RORC | |
| SCHEMBL21122113 | 0.89 | SCN9A (0.34) | SCN9ALSSSCN5AESR1RORC | |
| SCHEMBL21114159 | 0.85 | LSS (0.33) | SCN9ALSSSCN5ARORCALOX5AP | |
| SCHEMBL21114142 | 0.82 | SCN9A (0.36) | SCN9ARXRALSSSCN5AESR1 | |
| SCHEMBL21113977 | 0.81 | SCN9A (0.42) | SCN9ALSSSCN5AALOX5APFEN1 | |
| SCHEMBL21113933 | 0.80 | SCN9A (0.39) | SCN9ARXRALSSSCN5AESR1 | |
| SCHEMBL21114068 | 0.75 | RXRA (0.35) | SCN9ARXRALSSALOX5APFEN1 | |
| SCHEMBL21113916 | 0.74 | LSS (0.44) | SCN9ARXRALSSESR1RORC | |
| SCHEMBL21114181 | 0.74 | ALOX5AP (0.39) | SCN9ARXRALSSSCN5AALOX5AP | |
| SCHEMBL21114187 | 0.73 | LSS (0.47) | SCN9ARXRALSSESR1RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-07-11 | — | — | US | disclosed |
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190210973-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF CYSTIC FIBROSIS | CFTR, SLC26A4, SERPINB1 | SCN9A 973/4885RXRA 687/4885LSS 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.